At the annual “SEC Speaks” conference on February 19, 2016 in Washington, DC, the head of the SEC’s FCPA Unit, Kara Brockmeyer, warned pharmaceutical companies that their industry will be under renewed scrutiny in 2016. She said the SEC “is going back to the pharma industry after a break for a period of years.” Brockmeyer also highlighted increased international cooperation that will make government enforcement easier going forward.